The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology...
We use essential cookies to make the site work.
The newsletter signup form (powered by Substack) is always enabled and may load content from Substack.
You can choose whether to allow analytics/marketing cookies.
Read our policy